Austin Charette's departure as Principal Accounting Officer of Agenus Inc was reported, effective May 29, 2026; the filing names no successor. As of November 15, 2026, Agenus Inc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 14, 2026 to August 11, 2026, naming 1 appointment and 1 departure (Form 8-K, May 15, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Agenus Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-11
- · In / out: Out · Person: Austin Charette · Role: Principal Accounting Officer · Effective: 2026-05-29 · 8-K, 2026-05-15
- · In / out: In · Person: Garo Armen · Role: Chief Financial Officer · Effective: 2026-01-08 · 8-K, 2026-01-14
Agenus Inc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-14 to 2026-08-11. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Agenus Inc files it.
Layoffs on record: 1 filing or notice, latest 2024-12-05 (layoff filings and notices).
Also on the record for Agenus Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G, by Eventide Asset Management, LLC | 5.4% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 6% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| July 17, 2026 | Stake report, Schedule 13G, by Raymond Debbane | 9.99% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 23, 2026 | Stake report, Schedule 13D, by ZYNEXT VENTURES USA LLC | 5.9% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 8.06% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 9.23% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Agenus Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Agenus Inc and the records around it.
Agenus Inc elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Eventide Asset Management, LLC also filed stake reports on 11 other companies: enGene Therapeutics Inc (Nov 2026), Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: DBV Technologies S.A. (Nov 2026), Rani Therapeutics Holdings, Inc. (Nov 2026), Silence Therapeutics plc (Nov 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Evommune, Inc. (Nov 2026), Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026)
Watch Agenus Inc
Get an email when Agenus Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Agenus Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Agenus Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Agenus Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-11 | Reported | not named in the filing | 8-K, 2026-08-11 | ||
| 2026-05-15 | Out | Principal Accounting Officer | 2026-05-29 | 8-K, 2026-05-15 | |
| 2026-01-14 | In | Chief Financial Officer | 2026-01-08 | 8-K, 2026-01-14 |
Why did they leave? What the filings say
Agenus Inc's filings state no reason for the departures below. Where a filing gives none, it says so here; nothing is inferred.
- Austin Charette, Principal Accounting Officer (filed 2026-05-15): the filing states no reason.
Who leads Agenus Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Principal Accounting Officer: Austin Charette, departure reported, effective 2026-05-29 (filed 2026-05-15). No successor is named in these filings.
- Chief Financial Officer: Garo Armen, appointed, effective 2026-01-08 (filed 2026-01-14).
New leaders reset buying decisions — get the Full Report on Agenus Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Principal Accounting Officer at Agenus Inc, with the record behind each one.
Find candidates like Principal Accounting Officer at Agenus IncEvery change, in the filing's words
Reported
Mr. Marcucci was also appointed to serve as a member of the Board's Corporate Governance and Nominating Committee.
- On August 5, 2026, the board of directors (the "Board") of Agenus Inc., a Delaware corporation (the "Company"), increased the size of the Board from six (6) to seven (7) directors and appointed Marco Tullio Marcucci to fill the resulting vacancy as a Class II director, to serve until the Company's 2029 annual meeting of stockholders and until his successor is duly elected and qualified, effective immediately.
- Following Mr. Marcucci's appointment, the Board consists of seven (7) directors, including Brian Corvese and Timothy R. Wright, serving as Class I directors; Garo Armen, Jennifer Buell and Marco Tullio Marcucci, serving as Class II directors; and Susan Hirsch and Thomas Harrison, serving as Class III directors.
- Mr. Marcucci, age 55, is an attorney based in Rome, Italy.
- Since 2003, he has practiced at Studio Legale Pecora Marcucci, where he advises individuals and companies on commercial and civil law, administrative and tax litigation, wealth management, capital markets investments, venture capital activities, and domestic and cross-border agreements.
- He previously served as in-house legal counsel at H3G S.p.A. in Rome and held earlier legal roles involving corporate law, competition law and transnational joint ventures.
- Mr. Marcucci has been admitted to the Bar Association of Rome since 2002 and to the Special Bar Association of the Supreme Court and High Courts since 2018.
Departing: Austin Charette, Principal Accounting Officer, effective 2026-05-29
On May 12, 2026, Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus Inc. (the "Company"), informed the Company he will be resigning effective May 29, 2026.
Appointed: Garo Armen, Chief Financial Officer, effective 2026-01-08
Effective January 8, 2026, Agenus Inc.'s (the "Company") Board of Directors appointed Dr. Garo Armen, the Company's current Chairman and Chief Executive Officer to serve as the Company's interim Chief Financial Officer ("CFO") and Principal Financial Officer.
- Dr. Armen, age 72, co-founded the Company in 1994.
- Under his leadership, Agenus has been advancing breakthrough scientific technologies and immunotherapeutic products.
- In addition, Dr. Armen oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors.
- Dr. Armen began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds (now Morgan Stanley).
- Dr. Armen received his PhD in physical chemistry from the City University of New York.
- There were no new arrangements or modifications to existing arrangements entered into with Dr. Armen in connection with his designation as the Company's interim CFO and Principal Financial Officer.
- Dr. Armen continues to receive his base salary and any potential bonus payments in Agenus stock rather than cash.
- Mr. Charette, age 37, joined the Company in August 2017 and has served as Senior Director, Financial Reporting and Compliance since January 2026 where he is responsible for the Company's external reporting, technical accounting, internal controls and implementation of new accounting standards.
Tools for this story
Each opens in a new tab, filled in for Agenus Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
